Publications

Authors: Sufyan Hussain, William Polonsky,  Renza Scibilia, Timor Glatzer  Abstract Advances in diabetes technologies such as continuous glucose monitoring (CGM) have provided significant opportunities to improve glycemic and quality-of-life outcomes for people with type 1 diabetes (T1D). The ambulatory glucose profile and the introduction of glucose thresholds helped a lot to identify patterns, which was the first step toward improving hyper-and hypoglycemia

Authors: Danielle M Hessler, William H Polonsky, Lisa Strycker, Diana Naranjo, Katherine Greenberg, Lawrence Fisher Abstract Aims: To document stability and change over time, define a minimal clinically important difference (MCID), and examine the predictive validity of the new Type 1 Diabetes Distress Assessment System (T1-DDAS). Methods: A total of 574 adults with type 1 diabetes recruited through national registries and previous studies completed the T1-DDAS Core

Authors: Tuğba Bi Lgehan, Elif Gencer Şendur, Özlem Canbolat, Emre Dünder, William H Polonsky Abstract Aims: This study aimed to examine the psychometric properties of the Turkish version of the Type 1 Diabetes Distress Scale METHODS: This methodological, descriptive, and correlational study was conducted with 292 individuals diagnosed with Type 1 diabetes. Data were collected between January 2024 and August 2024 using the “Information Form

Authors: Lawrence Fisher, Susan Guzman, William H Polonsky, Lisa Strycker, Katherine Greenberg, Danielle M Hessler Abstract Objective: To document the effectiveness of diabetes distress (DD) interventions and to suggest how the improvements in DD, documented in a previous report, led to improved glycemic outcomes. Methods: Individuals with T1D (n = 276) with elevated DD (>2 on T1 Diabetes Distress Scale) and HbA1c (>7.5 %) were assigned to:

Authors: Viral N Shah, Terry Dex, Luigi Meneghini, Amélie Rodrigues, William H Polonsky Abstract Aims: In Soli-CGM, treatment with iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL) in insulin-naive adults with suboptimally controlled type 2 diabetes (T2D; haemoglobin A1c 9%-13% on ≥2 oral antihyperglycaemic agents (OADs) ± glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy) increased time in range (TIR; primary

Authors: Marisa Kostiuk, E Seth Kramer, Andrea Nederveld, Danielle M Hessler, Lawrence Fisher, Jessica A Parascando, Tamara K Oser Abstract Purpose of review: Addressing diabetes distress (DD), the emotional demands of living with diabetes, is a crucial component of diabetes care. Most individuals with type 2 diabetes and approximately half of adults with type 1 diabetes receive their care in the

Authors: Daniel Moore, Natasha Leibel, William Polonsky, Henry Rodriguez. Plain language summary What is this summary about? Type 1 diabetes is an autoimmune disease. This means that the body’s immune system mistakenly attacks the beta cells, the type of cell that makes the hormone insulin, in the pancreas. Insulin allows a person to use energy from food and controls blood

Authors: William Polonsky, Emily Soriano, Lisa Strycker, Lawrence Fisher. Abstract Background: Recent advances in diabetes care and technology, such as real-time continuous glucose monitoring, can help people live more freely, with more flexibility and fewer constraints, thereby enhancing quality of life (QOL). To date, there has been no validated means for measuring this key psychological dimension. We developed the Diabetes

Authors: Katharine Barnard-Kelly, David Marrero, Maartie de Wit, Frans Pouwer, Kamlesh Khunti, Norbert Hermans, Jessica Pierce, Lori Laffel, Richard Holt, Tadei Battelino, Diana Naranjo, Jacqueline Fosbury, Lawrence Fisher, William Polonsky, Jill Weissberg-Benchell, Korey Hood, Oliver Schnell, Laurel Messer, Thomas Danne, Revital Nimri, Soren Akovlund, Julia Mader, Jennifer Sherr, Desmond Schatz, Simon O’Neill, Emma Doble, Marissa Town, Karin Lange, Carine de

Authors: Lawrence Fisher, Susan Guzman, William Polonsky, Danielle Hessler Abstract Aims: Diabetes distress (DD) refers to the emotional and behavioural challenges associated with managing this demanding chronic disease over time. DD is alarmingly common and it has a significant impact on self-management behaviours and clinical outcomes. Thus, there is growing recognition that DD is a pressing problem that deserves careful attention